Rapidemic develops a molecular point-of-care test for the diagnosis of sexually transmitted infections. Their proprietary technology increases the sensitivity and specificity of the reaction while keeping manipulations to a minimum. Its technology enables low-temperature diagnostics while safeguarding accuracy and reducing false positives.